Assess the prevalence of nonalcoholic fatty liver disease (NAFLD) and of liver fibrosis associated with nonalcoholic steatohepatitis in unselected patients with type 2 diabetes mellitus (T2DM). A total of 561 patients with T2DM (age: 60 ± 11 years; BMI: 33.4 ± 6.2 kg/m2; and HbA1c: 7.5 ± 1.8%) attending primary care or endocrinology outpatient clinics… Continue reading Advanced #Liver Fibrosis Is Common in Patients With Type 2 #Diabetes Followed in the Outpatient Setting: The Need for Systematic Screening
Tag: Diabetes
#Dapagliflozin and the Incidence of Type 2 #Diabetes in Patients With #Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis From DAPA-HF
The sodium–glucose cotransporter 2 inhibitor dapagliflozin reduced the risk of cardiovascular mortality and worsening heart failure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure (DAPA-HF) trial. This report explores the effect of dapagliflozin on incident type 2 diabetes (T2D) in the cohort without diabetes enrolled in the trial RESEARCH DESIGN AND METHODS… Continue reading #Dapagliflozin and the Incidence of Type 2 #Diabetes in Patients With #Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis From DAPA-HF
PAPPA-mediated adipose tissue remodeling mitigates insulin resistance and protects against #gestational #diabetes in mice and humans
Pregnancy is a physiological state of continuous adaptation to changing maternal and fetal nutritional needs, including a reduction of maternal insulin sensitivity allowing for appropriately enhanced glucose availability to the fetus. However, excessive insulin resistance in conjunction with insufficient insulin secretion results in gestational diabetes mellitus (GDM), greatly increasing the risk for pregnancy complications and… Continue reading PAPPA-mediated adipose tissue remodeling mitigates insulin resistance and protects against #gestational #diabetes in mice and humans
Effects of oral #semaglutide on energy intake, #food preference, #appetite, control of eating and body #weight in subjects with type 2 #diabetes
Aims To evaluate the effect of oral semaglutide on energy intake and appetite in subjects with type 2 diabetes (T2D). Materials and methods In this randomised, double‐blind, placebo‐controlled, two‐period cross‐over trial, 15 subjects with T2D received 12 weeks' treatment with once‐daily oral semaglutide (4‐week dose‐escalation from 3 to 7 to 14 mg) followed by placebo,… Continue reading Effects of oral #semaglutide on energy intake, #food preference, #appetite, control of eating and body #weight in subjects with type 2 #diabetes
Development of a #hypoglycaemia risk score to identify high‐risk individuals with advanced type 2 diabetes in DEVOTE
The ability to differentiate patient populations with type 2 diabetes at high risk of severe hypoglycaemia could impact clinical decision making. The aim of this study was to develop a risk score, using patient characteristics, that could differentiate between populations with higher and lower 2‐year risk of severe hypoglycaemia among individuals at increased risk of… Continue reading Development of a #hypoglycaemia risk score to identify high‐risk individuals with advanced type 2 diabetes in DEVOTE
Risk Factor Control and #Cardiovascular Event Risk in People With Type 2 #Diabetes in Primary and Secondary Prevention Settings
To examine the association between the degree of risk factor control and cardiovascular disease (CVD) risk in type 2 diabetes and to assess if the presence of cardio-renal disease modifies these relationships. A retrospective cohort study using data from English practices from CPRD GOLD (Clinical Practice Research Datalink) and the SCI-Diabetes dataset (Scottish Care Information-Diabetes),… Continue reading Risk Factor Control and #Cardiovascular Event Risk in People With Type 2 #Diabetes in Primary and Secondary Prevention Settings
Association of Baseline and Longitudinal Changes in Body Composition Measures With Risk of #Heart Failure and Myocardial #Infarction in Type 2 #Diabetes: Findings From the Look AHEAD Trial
#Smoking Cessation, #Weight Change, #Diabetes, and #Hypertension in Korean Adult
This study investigates the association of smoking cessation and postcessation weight gain with the development of type 2 diabetes mellitus and hypertension. Methods A total of 96,524 individuals without diabetes mellitus and hypertension aged ≥20 years between 2006 and 2008 were included, with follow-up until December 31, 2015. Smoking status and weight changes were monitored… Continue reading #Smoking Cessation, #Weight Change, #Diabetes, and #Hypertension in Korean Adult
Efficacy and Safety Over 2 Years of #Exenatide Plus #Dapagliflozin in the DURATION-8 Study: A Multicenter, Double-Blind, Phase 3, Randomized Controlled Trial
In patients with type 2 diabetes uncontrolled with metformin, exenatide once weekly (QW) plus dapagliflozin produced greater reductions in glycemic parameters (glycated hemoglobin [HbA1c], fasting plasma glucose [FPG], and 2-h postprandial glucose [2-h PPG]), weight, and systolic blood pressure (SBP) than exenatide QW or dapagliflozin alone after 28 weeks of treatment in DURATION-8. Following a… Continue reading Efficacy and Safety Over 2 Years of #Exenatide Plus #Dapagliflozin in the DURATION-8 Study: A Multicenter, Double-Blind, Phase 3, Randomized Controlled Trial
2 Medical News 